Jan 29, 2018
Cellect Biotechnology Announces $4 Million Registered Direct Offering
Jan 16, 2018
Cellect Announces Opening of a Second Clinical Trial Site and Approval from Safety Board (DSMB) for Dose Escalation
Jan 04, 2018
Cellect Announces Breakthrough Clinical Results
Nov 22, 2017
Cellect Biotechnology Ltd Provides Corporate Update and Reports Third Quarter 2017 Financial Results
Nov 10, 2017
Cellect CEO, Dr. Shai Yarkoni Selected as Keynote Speaker at the 11th World Congress of Regenerative Medicine & Stem Cell in Singapore
Oct 31, 2017
Cellect Chosen Among Selected Global Leaders Presenting at Bio-Europe 2017 Conference Addressing over 3,800 Industry Specialists from Over 2,000 World Leading Companies
Oct 25, 2017
Cellect Announces a Major Breakthrough of its ApoGraft(TM) Technology: Reporting Today Positive Results from a 20 Patients Trial With Tel-Aviv Ichilov Medical Center
Oct 19, 2017
Cellect Appoints Dr. Ronit Bakimer-Kleiner as Chief Development Officer
Sep 07, 2017
Cellect Biotechnology Announces $4.3 Million Raise in a Registered Direct Offering
Sep 05, 2017
FDA Grants Orphan Drug Status to Cellect's ApoGraft(TM) for Acute GvHD and Chronic GvHD
Sep 01, 2017
Cellect Shares Will Be Traded From Next Week Exclusively on NASDAQ
Aug 21, 2017
Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Aug 07, 2017
Cellect Engages Locust Walk to Support Business Development Activities for Cellect's ApoGraft(TM)
Jun 14, 2017
Following the US, Cellect Receives Russian Patent Covering Any Device and Method Using Cellect's Flagship Technology - the ApoGraft(TM)
Jun 12, 2017
Cellect Receives Notice of Allowance from the US Patent & Trademark Office
Jun 09, 2017
Cellect is Moving to Trade Exclusively on the NASDAQ
May 29, 2017
Cellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter 2017 Financial Results